Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Five Prime Therapeutics Inc

CUSIP: 33830X954 | 7 institutional holders

Quarters

Q1 2021 Q4 2020 Q3 2020 Q2 2020 Q1 2020

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile